10 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)Arterial Occlusive Diseases, Chronic Disease, Death, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, arteriosclerosis disorder, atherosclerosis, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, chronic renal failure syndrome, coronary artery disorder, diabetes mellitus, endocrine system disorder, glucose metabolism disease, heart disorder, kidney disorder, kidney failure, metabolic disease, myocardial ischemia, nervous system disorder, peripheral arterial disease, peripheral vascular disease, type 2 diabetes mellitus, urinary system disorder, vascular disorderActive, not recruitingPhase 32026-10-08NCT06383390
A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This ConditionDigestive System Diseases, fatty liver disease, liver disorder, metabolic dysfunction-associated steatotic liver diseaseRecruitingPhase 22026-10-08NCT05519475
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated CirrhosisDigestive System Diseases, Fibrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, bile duct disorder, biliary tract disorder, cholestasis, cirrhosis of liver, intrahepatic cholestasis, liver disorder, primary biliary cholangitisRecruitingPhase 32026-10-06NCT06051617
A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing CholangitisCholangitis, Sclerosing, Digestive System Diseases, bile duct disorder, biliary tract disorder, cholangitis, primary sclerosing cholangitisRecruitingPhase 32026-10-01NCT07387549
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver FibrosisDigestive System Diseases, Fibrosis, Fibrosis, Liver, Pathologic Processes, Pathological Conditions, Signs and Symptoms, cirrhosis of liver, liver disorderRecruitingPhase 32026-10-01NCT06632444
A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLDDigestive System Diseases, fatty liver disease, liver disorder, metabolic dysfunction-associated steatotic liver diseaseRecruitingPhase 22026-09-29NCT07527910
A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)Digestive System Diseases, Fibrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, cirrhosis of liver, liver disorder, metabolic dysfunction-associated steatohepatitisActive, not recruitingPhase 32026-07-08NCT05500222
Study of E7386 in Participants With Selected Advanced NeoplasmsDigestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasmActive, not recruitingPhase 12026-06-08NCT03264664
Study of Seladelpar in Participants With Primary Biliary Cholangitis (PBC)Digestive System Diseases, Fibrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, bile duct disorder, biliary tract disorder, cholestasis, cirrhosis of liver, intrahepatic cholestasis, liver disorder, primary biliary cholangitisActive, not recruitingPhase 32026-05-04NCT03301506
A Longitudinal Observational Study of the Natural History and Management of Patients With HCCDigestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Site, liver disorder, neoplasmActive, not recruitingNot stated2026-04-17NCT02954094